Emory Vaccine and Treatment Evaluation Unit - KidCOVE
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3UM1AI148576-02S2
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$1,475,091Funder
National Institutes of Health (NIH)Principal Investigator
Unspecified Nadine Georges Rouphael, Evan J Anderson, Carlos Del RioResearch Location
United States of AmericaLead Research Institution
Emory UniversityResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 2 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Children (1 year to 12 years)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Narrative The Emory VTEU will participate and enroll children into "A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age (KidCOVE)".